Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply

Affiliations

¹ Department of Internal Medicine, Ditmanson Medication Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
² Departments of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

Comment

P-Y Chen et al. Aliment Pharmacol Ther. 2017 Feb.

. 2017 Feb;45(4):573.

doi: 10.1111/apt.13909.

¹ Department of Internal Medicine, Ditmanson Medication Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
² Departments of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.

No abstract available

Comment on

Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection.
Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Chen PY, et al. Aliment Pharmacol Ther. 2016 Sep;44(5):427-37. doi: 10.1111/apt.13712. Epub 2016 Jun 30. Aliment Pharmacol Ther. 2016. PMID: 27363687
Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection.
Zamani M, Shokri-Shirvani J, Zamani V. Zamani M, et al. Aliment Pharmacol Ther. 2017 Feb;45(4):572-573. doi: 10.1111/apt.13881. Aliment Pharmacol Ther. 2017. PMID: 28074507 No abstract available.